These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21463140)

  • 1. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J; Tonia T; Schwarzer G
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
    Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
    Repetto L; Moeremans K; Annemans L;
    Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia management in oncology and hematology.
    Spivak JL; Gascón P; Ludwig H
    Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
    Spaëth D
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chemotherapy-induced anemia].
    Kadokura G; Katsumata N
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.